SAN
DIEGO, May 28, 2024 /PRNewswire/ -- Illumina Inc.
(NASDAQ: ILMN), a global leader in DNA sequencing and array-based
technologies, today published its fifth annual Corporate Social
Responsibility (CSR) Report. The report highlights the company's
ongoing commitments and progress made in 2023 toward advancing
human health by serving as a champion for patients, communities,
employees, and the planet.
"At Illumina, we are guided by our mission to improve human
health by unlocking the power of the genome," said Jacob Thaysen, CEO of Illumina. "Our customers,
partners, and employees continue taking bold, meaningful steps to
accelerate access to genomics, empower our communities, integrate
environmental sustainability into our business strategy, nurture
our people, and operate responsibly."
Illumina's CSR program is rooted in four key focus areas, and
the company's 2023 CSR Report demonstrates progress in each:
- Accelerating access to genomics: Illumina continues to
bring the benefits of genomics to more people by driving down the
cost of sequencing, expanding into new markets, and increasing the
diversity of genomic data. In 2023, Illumina trained more than
27,000 health care professionals and continued its advocacy for
health care coverage for genomic testing, which increased from 1.2
billion to 1.3 billion. The company also launched several new
products, including the NovaSeq™ X Series, powered by XLEAP-SBS™
chemistry; the TruSight™ Oncology 500 ctDNA v2 research assay,
enabling comprehensive genomic profiling from liquid biopsy
samples; and the 25B flow cell, which
can generate tens of thousands of whole genomes per year at the
lowest cost per sample of any Illumina platform.
- Nurturing our people and communities: In 2023, Illumina
maintained a zero net pay gap for the fifth consecutive year and
reached 45% female representation in the workforce, with a 5%
increase in female leadership roles over the last three years.
Illumina also strives to create a purpose-driven culture, and in
2023, nearly 60% of employees worldwide participated in charitable
giving and volunteering.
- Integrating environmental stewardship: As the genomics
industry leader, Illumina plays a crucial role in contributing to a
healthier planet. The Illumina NovaSeq X Series, which debuted in
2023, uses significantly more sustainable reagents, resulting in
90% less packaging weight and waste, 50% less plastic, and a 61%
reduction in climate change impact. Additionally, 100% of
Illumina's global electricity consumption came from renewable
sources for the second consecutive year.
- Operating responsibly: In 2023, Illumina strengthened
its dedication to ethical business practices and operational
integrity by ensuring that 100% of its core facilities participated
in third-party audit programs. Illumina also expanded its ISO data
privacy certification to include additional products and completed
the EU-US and Swiss-US Data Privacy Framework (DPF)
Self-Certification and ISO 27701 certification. Additionally,
Illumina continues to exercise strong corporate governance with an
independent Board of Directors (all independent with the exception
of the CEO), an independent Board Chair, and 75% of standing
committees chaired by women.
The full report is available on Illumina's CSR website.
Forward-Looking Statements
This communication contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements regarding mandates, the future, business
plans and other statements that are not historical in nature. These
statements are made on the basis of Illumina's views and
assumptions regarding future events and business performance and
plans as of the time the statements are made. These forward-looking
statements may be accompanied by such words as "anticipate,"
"believe," "could," "estimate," "expect," "forecast," "intend,"
"may," "plan," "potential," "project," "target," "will" and other
words and terms of similar meaning. Illumina does not undertake any
obligation to update these statements unless required by applicable
laws or regulations, and you should not place undue reliance on
forward-looking statements. Specific factors are set forth in
Illumina's Annual Report on Form 10-K for the year ended
January 1, 2023 under the caption
"Risk Factors", in information disclosed in public conference
calls, the date and time of which are released beforehand, and in
filings with the Securities and Exchange Commission including,
among others, quarterly reports on Form 10-Q.
About Illumina
Illumina is improving human health by unlocking the power of the
genome. Our focus on innovation has established us as a global
leader in DNA sequencing and array-based technologies, serving
customers in the research, clinical, and applied markets. Our
products are used for applications in the life sciences, oncology,
reproductive health, agriculture, and other emerging segments. To
learn more, visit illumina.com and connect with us on X, Facebook,
LinkedIn, Instagram, TikTok, and YouTube.
Contacts
Investors:
Salli Schwartz
858-291-6421
IR@illumina.com
Media:
Samantha Beal
PR@illumina.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/illumina-releases-2023-corporate-social-responsibility-report-302157056.html
SOURCE Illumina, Inc.